U.S. Markets closed
  • S&P 500

    -64.76 (-1.72%)
  • Dow 30

    -486.29 (-1.62%)
  • Nasdaq

    -198.87 (-1.80%)
  • Russell 2000

    -42.72 (-2.48%)
  • Crude Oil

    -4.06 (-4.86%)
  • Gold

    -29.40 (-1.75%)
  • Silver

    -0.76 (-3.90%)

    -0.0131 (-1.3298%)
  • 10-Yr Bond

    -0.0110 (-0.30%)
  • Vix

    +2.57 (+9.40%)

    -0.0413 (-3.6730%)

    +1.0550 (+0.7412%)

    -177.09 (-0.93%)
  • CMC Crypto 200

    -9.92 (-2.23%)
  • FTSE 100

    -140.92 (-1.97%)
  • Nikkei 225

    -159.27 (-0.58%)

Wall Street Analysts are Recommending These 10 Stocks in September

·5 min read

In this article, we will take a look at the 10 stocks recommended by analysts in September. If you want to see some more stocks recently recommended by analysts, go directly to Wall Street Analysts are Recommending These 5 Stocks in September.

A stock rating usually enables investors to pick the right stocks for their portfolios. Therefore, it is always preferable to go through analysts' recommendations before buying a stock. Analysts recently turned bullish on biotechnology company Moderna, Inc. (NASDAQ:MRNA), electric vehicle giant Tesla, Inc. (NASDAQ:TSLA) and video streaming behemoth Netflix, Inc. (NASDAQ:NFLX).

In addition, market research firms also improved their ratings for Salesforce, Inc. (NYSE:CRM) and Mettler-Toledo International Inc. (NYSE:MTD). Check out the complete article below to see why Wall Street analysts are recommending these 10 stocks in September. We picked stocks that recently received positive analyst ratings and bullish comments from Wall Street experts.

10. Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Number of Hedge Fund Holders: 19

Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a biopharmaceutical company engaged in developing novel treatments for central nervous system (CNS) disorders. Mizuho analyst Graig Suvannavejh issued a "Buy" rating for the stock on Wednesday, September 7, 2022.

Suvannavejh was primarily moved by Axsome's drug portfolio targeting CNS conditions with unmet medical needs. He believes the company's drug candidates address large markets. Suvannavejh also raised his price target for Axsome Therapeutics, Inc. (NASDAQ:AXSM) from $49 per share to $76 per share.

Last month, Axsome Therapeutics, Inc. (NASDAQ:AXSM) received FDA approval for Auvelity for treating a major depressive condition in adults. The company plans to roll out the drug commercially in the U.S. by the end of this year.

9. PPG Industries, Inc. (NYSE:PPG)

Number of Hedge Fund Holders: 22

Redburn analyst Tony Jones improved his ratings for PPG Industries, Inc. (NYSE:PPG) from "Neutral" to "Buy" on Tuesday, September 6, 2022. Jones thinks the underperformance by paints and coatings stocks is over and they are set to make a rebound.

PPG Industries, Inc. (NYSE:PPG) is a leading supplier of paints and coatings. The company was founded way back in 1883, making it one of the oldest players in the markets it operates. Moreover, it has decades-long experience in progressing in tough times like these.

Earlier this year, investment management firm ClearBridge Investments also discussed PPG Industries, Inc. (NYSE:PPG) in its first-quarter 2022 investor letter, stating:

"While commodities-exposed areas of the materials sector such as mining and steel fared well in the quarter, we tend to have less direct exposure to commodities across our portfolio. Holdings like paint and coating company PPG Industries (NYSE:PPG) that use natural gas and oil related products as feedstock into their products faced sharp input cost escalation, driving meaningful margin compression, which was not well-received by investors. While negative in the short term, we remain confident that the company will be able to adjust pricing accordingly and recover margins over the medium term."

Like PPG Industries, Inc. (NYSE:PPG), analysts also raised their ratings for Moderna, Inc. (NASDAQ:MRNA), Tesla, Inc. (NASDAQ:TSLA) and Netflix, Inc. (NASDAQ:NFLX), in September.

8. Bilibili Inc. (NASDAQ:BILI)

Number of Hedge Fund Holders: 25

Shares of Bilibili Inc. (NASDAQ:BILI) rose nearly five percent on Wednesday, September 7, 2022, after receiving an upgrade from JPMorgan. The research firm upgraded the Chinese video sharing platform from "Neutral" to "Overweight," and issued a price target of $35 for the stock.

JPMorgan analyst Daniel Chen expects Bilibili Inc. (NASDAQ:BILI) to improve its margin in the second half. He thinks the company's new games and Story Mode would drive its top-line growth.

Meanwhile, Bilibili Inc. (NASDAQ:BILI) announced mixed financial results for the second quarter on Thursday, September 8, 2022. The company reported an adjusted loss of 4.98 yuan per ADS, wider than analysts' average estimate for a loss of 4.42 yuan per ADS. Revenue for the quarter rose 9.2 percent on a year-over-year basis to 4.91 billion, just ahead of the expectations of 4.89 billion yuan.

7. First Solar, Inc. (NASDAQ:FSLR)

Number of Hedge Fund Holders: 26

Goldman Sachs turned bullish on First Solar, Inc. (NASDAQ:FSLR) on Wednesday, September 7, 2022. The research firm upgraded the solar technology company from "Sell" to "Buy" and lifted its price target from $60 per share to $172 per share.

Goldman Sachs analyst Brian Lee thinks First Solar, Inc. (NASDAQ:FSLR) would benefit from the Inflation Reduction Act (IRA). First Solar shares rose over three percent in pre-market trading Thursday, September 8, following the upgrade.

Overall, First Solar, Inc. (NASDAQ:FSLR) shares have jumped more than 30 percent over the last month. Much of that gain has been attributed to the approval of the climate-focused IRA bill in August. The IRA bill includes a hefty amount of $369 billion primarily for reducing carbon footprint.

Following the bill's approval, First Solar, Inc. (NASDAQ:FSLR) announced that it would build a new panel facility in the U.S. for roughly $1.2 billion. The announcement was intended to avail new tax credits from the government under IRA.

Like First Solar, Inc. (NASDAQ:FSLR), Moderna, Inc. (NASDAQ:MRNA), Tesla, Inc. (NASDAQ:TSLA) and Netflix, Inc. (NASDAQ:NFLX), were also recently upgraded by analysts.

6. Roku, Inc. (NASDAQ:ROKU)

Number of Hedge Fund Holders: 34

Shares of Roku, Inc. (NASDAQ:ROKU) marginally moved up in pre-market trading Thursday, September 8, 2022, after Pivotal Research improved its ratings for the maker of digital media players from "Sell" to "Hold."

Analyst Jeffrey Wlodarczak thinks the stock now offers a balanced risk/reward. He also advised bearish investors to realize profits on their short positions in the stock. Wlodarczak kept his price target of $60 per share for Roku, Inc. (NASDAQ:ROKU).

Roku, Inc. (NASDAQ:ROKU) shares have struggled to gain value so far in 2022. The stock is down about 70 percent on a year-to-date basis.

Click to continue reading and see Wall Street Analysts are Recommending These 5 Stocks in September.


Suggested articles:

Disclosure: None. Wall Street Analysts are Recommending These 10 Stocks in September is originally published on Insider Monkey.